← Back to Search

Anti-angiogenic agent

single group for Cancer

Phase 4
Waitlist Available
Research Sponsored by Sun Yat-sen University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up eight weeks
Awards & highlights

Study Summary

The tolerability of apatinib, an effective antiangiogenic agent, varies greatly in patients with stage IV cancer during treatment. This study will include patients with advanced (stage IV) gastric cancer, non-small-cell lung cancer (NSCLC), breast cancer or ovarian cancer, who will be administered apatinib treatment starting from 250 mg Qd and closely monitored for ADRs during the period of apatinib treatment. Meanwhile, relevant assay technologies will be used to precisely detect changes of various biomarkers in the patients treated by apatinib, with the aim of identifying biomarkers related to their prognosis and relevant complications so as to screen out the favored population, establish the drug's indication(s) and reduce relevant side effects.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~eight weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and eight weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
metastasis

Side effects data

From 2013 Phase 3 trial • 267 Patients • NCT01512745
48%
proteinuria
40%
leukopenia
38%
neutropenia
35%
hypertension
28%
hand-foot syndrome
28%
elevated transaminase
25%
thrombocytopenia
25%
anemia
24%
hyperbilirubinemia
20%
ALP increased
20%
bleeding
20%
fatigue
16%
abdominal pain
16%
elevated GGT
15%
decreased appetite
13%
hypoproteinemia
11%
diarrhea
10%
elevated LDH
3%
Gastrointestinal bleeding
1%
Abdominal pain
100%
80%
60%
40%
20%
0%
Study treatment Arm
Apatinib
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: single groupExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Rivoceranib
Not yet FDA approved

Find a Location

Who is running the clinical trial?

Sun Yat-sen UniversityLead Sponsor
1,519 Previous Clinical Trials
3,449,537 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations
Hao Long 2018. "Study on the Adverse Drug Reactions (ADRs) of Apatinib and Their Biomarker Correlations". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03475589.
~30 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top